<strong>Objective:</strong> Therapeutic results of relapsed/refractory mantle cell lymphoma (R/R MCL) are very disappointing at present, and there is no standard effective treatment regimen. Ibrutinib has ...<strong>Objective:</strong> Therapeutic results of relapsed/refractory mantle cell lymphoma (R/R MCL) are very disappointing at present, and there is no standard effective treatment regimen. Ibrutinib has been proved to be effective for R/R MCL, however, the sample size of these individual clinical studies was relatively small. Hence, current clinical experience in its usage is still limited. It is necessary to systematically analyze the efficacy and adverse reactions of ibrutinib in the treatment of R/R MCL. <strong>Methods:</strong> The PubMed, Cochrane Library, and Embase databases were searched using English search terms, mantle cell lymphoma, MCL, and ibrutinib;the VIP, Wanfang, and China National Knowledge Infrastructure (CNKI) databases were searched using the Chinese search terms, ibrutinib and mantle cell lymphoma. The extracted data were subjected to meta-analysis using R software to deduce the effective rate and occurrence rate of serious adverse reactions. <strong>Results:</strong> A total of 12 cohort studies were included in this analysis. The results demonstrated that ibrutinib could be an efficient therapy regimen for R/R MCL patients and the effect of combination therapy was better than that of single-drug therapy. During the treatment with ibrutinib, the adverse reactions mainly included hematological toxicity, infection, atrial fibrillation, and bleeding. <strong>Discussion:</strong> Our analysis showed ibrutinib is an optimal second-line treatment for R/R MCL, and the combination therapy is more effective than monotherapy as it was well-tolerated by the patients. Therefore, the combination of other drugs for R/R MCL should be considered for patients with poor efficacy of ibrutinib alone or relapse after treatment.展开更多
乳蛋白是生命最初阶段中最为重要的营养功能成分,并且种类多样、含量丰富。通过一系列的遗传改变、丰富的蛋白质翻译后修饰,使乳蛋白的构成变得非常复杂、数量异常庞大。采用蛋白质组学方法对乳蛋白进行系统、整体地研究,可以认识乳蛋...乳蛋白是生命最初阶段中最为重要的营养功能成分,并且种类多样、含量丰富。通过一系列的遗传改变、丰富的蛋白质翻译后修饰,使乳蛋白的构成变得非常复杂、数量异常庞大。采用蛋白质组学方法对乳蛋白进行系统、整体地研究,可以认识乳蛋白质在构成以及调控一些生命活动中的规律。这样能够非常全面、深入地表明乳蛋白质的表达水平。本文阐述了蛋白质组学中的主要技术,包括双向电泳技术、高效液相色谱技术、同位素标记相对和绝对定量(isobaric tags for relative and absolute quantitation,iTRAQ)技术、质谱技术以及生物信息学技术。分别讨论了蛋白质组学技术在人乳、牛乳中的应用,并对人乳与牛乳的差异蛋白质组学进行讨论。利用蛋白质组学技术分析人乳与牛乳蛋白,能够更有目的地加强对人乳与牛乳的认识,旨在为婴幼儿食品以及乳制品提供理论依据。展开更多
文摘<strong>Objective:</strong> Therapeutic results of relapsed/refractory mantle cell lymphoma (R/R MCL) are very disappointing at present, and there is no standard effective treatment regimen. Ibrutinib has been proved to be effective for R/R MCL, however, the sample size of these individual clinical studies was relatively small. Hence, current clinical experience in its usage is still limited. It is necessary to systematically analyze the efficacy and adverse reactions of ibrutinib in the treatment of R/R MCL. <strong>Methods:</strong> The PubMed, Cochrane Library, and Embase databases were searched using English search terms, mantle cell lymphoma, MCL, and ibrutinib;the VIP, Wanfang, and China National Knowledge Infrastructure (CNKI) databases were searched using the Chinese search terms, ibrutinib and mantle cell lymphoma. The extracted data were subjected to meta-analysis using R software to deduce the effective rate and occurrence rate of serious adverse reactions. <strong>Results:</strong> A total of 12 cohort studies were included in this analysis. The results demonstrated that ibrutinib could be an efficient therapy regimen for R/R MCL patients and the effect of combination therapy was better than that of single-drug therapy. During the treatment with ibrutinib, the adverse reactions mainly included hematological toxicity, infection, atrial fibrillation, and bleeding. <strong>Discussion:</strong> Our analysis showed ibrutinib is an optimal second-line treatment for R/R MCL, and the combination therapy is more effective than monotherapy as it was well-tolerated by the patients. Therefore, the combination of other drugs for R/R MCL should be considered for patients with poor efficacy of ibrutinib alone or relapse after treatment.
文摘乳蛋白是生命最初阶段中最为重要的营养功能成分,并且种类多样、含量丰富。通过一系列的遗传改变、丰富的蛋白质翻译后修饰,使乳蛋白的构成变得非常复杂、数量异常庞大。采用蛋白质组学方法对乳蛋白进行系统、整体地研究,可以认识乳蛋白质在构成以及调控一些生命活动中的规律。这样能够非常全面、深入地表明乳蛋白质的表达水平。本文阐述了蛋白质组学中的主要技术,包括双向电泳技术、高效液相色谱技术、同位素标记相对和绝对定量(isobaric tags for relative and absolute quantitation,iTRAQ)技术、质谱技术以及生物信息学技术。分别讨论了蛋白质组学技术在人乳、牛乳中的应用,并对人乳与牛乳的差异蛋白质组学进行讨论。利用蛋白质组学技术分析人乳与牛乳蛋白,能够更有目的地加强对人乳与牛乳的认识,旨在为婴幼儿食品以及乳制品提供理论依据。